Research
Hormonal
GLP-1 receptor agonists reduce the risk of major adverse cardiovascular events (MACE), death, and stroke in patients with type 2 diabetes.
If you have type 2 diabetes, GLP-1 receptor agonists can significantly lower your risk of heart attacks, strokes, and death. This benefit is independent of weight loss and is supported by large-scale data involving over 60,000 patients.
StrongSupportsVERY_HIGH confidence
a recent meta-analysis assessing CV outcome of different GLP-1R agonists across eight CV outcome trials comprising 60,080 patients with T2D. It demonstrated that GLP-1R agonists reduce the risk of a major adverse cardiovascular event (MACE) by 14%, death by 13%, non-fatal stroke by 12%, and broad composite kidney outcome by 17% (144).
Why this rating
Based on a meta-analysis of 8 trials with >60,000 patients.
Source
Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
Qiming Tan et al. · Frontiers in Endocrinology · 2022
narrative_reviewCited 142×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →